SG10201912150TA - Anti-trem2 antibodies and methods of use thereof - Google Patents
Anti-trem2 antibodies and methods of use thereofInfo
- Publication number
- SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238044P | 2015-10-06 | 2015-10-06 | |
| US201662369666P | 2016-08-01 | 2016-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912150TA true SG10201912150TA (en) | 2020-02-27 |
Family
ID=57178515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912150TA SG10201912150TA (en) | 2015-10-06 | 2016-10-06 | Anti-trem2 antibodies and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330335A1 (enExample) |
| EP (1) | EP3359569A2 (enExample) |
| JP (2) | JP7725185B2 (enExample) |
| KR (1) | KR20180068999A (enExample) |
| CN (2) | CN108738323B (enExample) |
| AU (2) | AU2016334051B2 (enExample) |
| CA (1) | CA2997960A1 (enExample) |
| SG (1) | SG10201912150TA (enExample) |
| WO (1) | WO2017062672A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| EP3452508A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| AU2017300040A1 (en) * | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| EP3555841A4 (en) * | 2016-12-13 | 2020-05-20 | Akili Interactive Labs, Inc. | BIOMARKER IDENTIFICATION PLATFORM USING NAVIGATION TASKS AND TREATMENTS USING NAVIGATION TASKS |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| ES3014942T3 (en) * | 2017-06-21 | 2025-04-28 | Univ North Carolina Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| AU2018304711B2 (en) | 2017-07-20 | 2025-04-10 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| DK3601358T5 (da) * | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| PE20210115A1 (es) * | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| KR102860409B1 (ko) | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CA3100398A1 (en) * | 2018-05-18 | 2019-11-21 | Macrogenics, Inc. | Optimized gp41-binding molecules and uses thereof |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| KR20210057113A (ko) * | 2018-09-11 | 2021-05-20 | 워싱턴 유니버시티 | 항-trem-2 작용제 항체 |
| WO2020072996A1 (en) * | 2018-10-05 | 2020-04-09 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| JP7709376B2 (ja) * | 2018-10-23 | 2025-07-16 | ブイオーアール バイオファーマ インコーポレーテッド | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 |
| KR102156165B1 (ko) * | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| WO2020112889A2 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| CA3122725A1 (en) * | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| CA3120875A1 (en) * | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| AU2020219374A1 (en) * | 2019-02-08 | 2021-07-01 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3927743A1 (en) * | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| AU2020228660A1 (en) * | 2019-02-28 | 2021-08-26 | Inspirna, Inc. | APOE genotyping in cancer prognostics and treatment |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN110320368A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| PH12022551228A1 (en) * | 2019-11-22 | 2023-06-14 | Lilly Co Eli | Trem2 antibodies and uses thereof |
| WO2021113655A1 (en) | 2019-12-05 | 2021-06-10 | Alector Llc | Methods of use of anti-trem2 antibodies |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| TWI890727B (zh) * | 2020-01-13 | 2025-07-21 | 美商戴納立製藥公司 | 抗trem2 抗體及其使用方法 |
| KR20220131246A (ko) * | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| EP4110814A1 (en) * | 2020-02-24 | 2023-01-04 | Alector LLC | Methods of use of anti-trem2 antibodies |
| WO2021202807A1 (en) | 2020-03-31 | 2021-10-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| KR20230005848A (ko) * | 2020-04-03 | 2023-01-10 | 알렉터 엘엘씨 | 항-trem2 항체의 사용 방법 |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| MA60122B1 (fr) * | 2020-06-26 | 2025-07-31 | Bioarctic Ab | Anticorps se liant à la protofibrille d'alpha-synucléine |
| CR20230069A (es) * | 2020-08-05 | 2023-08-16 | Vigil Neuroscience Inc | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
| CA3203308A1 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| KR20230130630A (ko) * | 2020-12-04 | 2023-09-12 | 비질 뉴로사이언스 인코포레이티드 | Trem2 작용제를 사용한 atp-결합 카세트 수송체 1 기능장애와 관련된 질환의 치료 |
| WO2022159620A1 (en) * | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| CN112979795B (zh) * | 2021-02-26 | 2022-07-08 | 深圳市亚辉龙生物科技股份有限公司 | 抗体组合产品及其在新冠肺炎检测中应用 |
| WO2022195287A1 (en) * | 2021-03-19 | 2022-09-22 | Bicycletx Limited | Bicyclic peptide ligands specific for trem2 |
| EP4337317A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
| WO2022245553A2 (en) * | 2021-05-19 | 2022-11-24 | Signablk, Inc. | Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof |
| WO2023022729A1 (en) * | 2021-08-20 | 2023-02-23 | Tasrif Pharmaceutical, LLC | Antibodies and antigen binding fragments against cd155 methods of use thereof |
| WO2023039450A2 (en) * | 2021-09-07 | 2023-03-16 | Duke University | Compositions and methods for treatment of retinal degeneration |
| WO2023086799A1 (en) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists |
| MX2024007263A (es) | 2021-12-17 | 2024-08-09 | Denali Therapeutics Inc | Modificación de polipéptidos, bibliotecas y cadena pesada cd98 modificada y polipéptidos de unión al receptor de transferrina. |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| KR20240149428A (ko) | 2022-02-23 | 2024-10-14 | 알렉터 엘엘씨 | 항-trem2 항체의 사용 방법 |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2023212707A2 (en) * | 2022-04-29 | 2023-11-02 | The Children's Medical Center Corporation | Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology |
| WO2024052343A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
| WO2024182318A2 (en) * | 2023-02-28 | 2024-09-06 | Kodiak Sciences Inc. | Antibodies to htra1 and conjugates thereof |
| WO2024226569A1 (en) * | 2023-04-24 | 2024-10-31 | The Research Foundation For The State University Of New York | Immunogenicity screening method |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| CN119529096A (zh) * | 2023-12-21 | 2025-02-28 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025194147A1 (en) * | 2024-03-15 | 2025-09-18 | The Children's Medical Center Corporation | Therapeutic modulation of trem2 and uses thereof in retinal degeneration |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| JP2004073182A (ja) * | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| WO2004058178A2 (en) * | 2002-12-23 | 2004-07-15 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| MX2007008017A (es) | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA3187687A1 (en) | 2007-09-14 | 2009-03-19 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US20100203047A1 (en) * | 2007-10-05 | 2010-08-12 | University Of Maryland, Baltimore | Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| CN102770456B (zh) * | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| US20170240631A1 (en) * | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
-
2016
- 2016-10-06 US US15/766,363 patent/US20190330335A1/en not_active Abandoned
- 2016-10-06 CN CN201680070761.1A patent/CN108738323B/zh active Active
- 2016-10-06 CA CA2997960A patent/CA2997960A1/en active Pending
- 2016-10-06 CN CN202310465565.6A patent/CN117069841A/zh active Pending
- 2016-10-06 AU AU2016334051A patent/AU2016334051B2/en active Active
- 2016-10-06 SG SG10201912150TA patent/SG10201912150TA/en unknown
- 2016-10-06 KR KR1020187012495A patent/KR20180068999A/ko not_active Ceased
- 2016-10-06 EP EP16784666.6A patent/EP3359569A2/en active Pending
- 2016-10-06 JP JP2018517785A patent/JP7725185B2/ja active Active
- 2016-10-06 WO PCT/US2016/055828 patent/WO2017062672A2/en not_active Ceased
-
2023
- 2023-02-17 US US18/171,291 patent/US20230295297A1/en active Pending
- 2023-04-04 JP JP2023060952A patent/JP2023093528A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200443A patent/AU2024200443A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3359569A2 (en) | 2018-08-15 |
| CA2997960A1 (en) | 2017-04-13 |
| CN108738323A (zh) | 2018-11-02 |
| AU2016334051A1 (en) | 2018-04-12 |
| US20230295297A1 (en) | 2023-09-21 |
| CN117069841A (zh) | 2023-11-17 |
| KR20180068999A (ko) | 2018-06-22 |
| AU2024200443A1 (en) | 2024-04-04 |
| WO2017062672A3 (en) | 2017-05-26 |
| JP7725185B2 (ja) | 2025-08-19 |
| WO2017062672A2 (en) | 2017-04-13 |
| JP2023093528A (ja) | 2023-07-04 |
| CN108738323B (zh) | 2023-05-26 |
| AU2016334051B2 (en) | 2023-10-26 |
| JP2018537956A (ja) | 2018-12-27 |
| US20190330335A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL257636A (en) | Anti-tigit antibodies and methods of use | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| SG11201803567XA (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL259681A (en) | New antibodies against claudin and methods of using them | |
| ZA202001985B (en) | Anti-htra1 antibodies and methods of use thereof | |
| ES3049257T3 (en) | Anti-c1s antibodies and methods of use thereof |